Survival Benefit of ARSI Therapy in Japanese mCSPC: A Systematic Review and Meta-Analysis. | ClinicLens
Randomized clinical trials have shown that second-generation androgen receptor signaling inhibitors (ARSIs) improve overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC). In Japan, combined androgen blockade (CAB) has been widely used as conventional ho
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.